FDA Begins Large Safety Review Of Abortion Pill Mifepristone
On Thursday, June 4, 2026, the Food and Drug Administration began a large retrospective safety review of the abortion pill mifepristone covering hundreds of thousands of cases.[1]
Agency officials expect to release interim results in July 2026, though final timing will depend on a planned secondary analysis.
On May 4, 2026, the Fifth U.S. Circuit Court of Appeals temporarily reinstated an in-person dispensing rule for mifepristone, but the Supreme Court allowed mail delivery to continue while the Louisiana case proceeds. HHS Secretary Robert F. Kennedy Jr. told GOP state attorneys general in September 2025 that the FDA was reviewing mifepristone's safety and real-world outcomes.
The review comes as courts and state officials press disputes over access and dispensing rules, and its findings could influence both policy and ongoing litigation over mifepristone.
Show source details & analysis (1 source)
📌 Key Facts
- On Thursday, June 4, 2026, a senior FDA official confirmed the agency has begun a retrospective safety study of mifepristone covering hundreds of thousands of cases.
- Interim results of the mifepristone safety review could be released in July 2026, with final timing dependent on a planned secondary analysis.
- HHS Secretary Robert F. Kennedy Jr. previously told GOP state attorneys general in September 2025 that FDA was reviewing mifepristone’s safety and real‑world outcomes.
- On May 4, 2026, the Fifth Circuit temporarily reinstated an in‑person dispensing rule for mifepristone, but the Supreme Court the following week allowed mail delivery to continue while the Louisiana case proceeds.
📰 Source Timeline (1)
Follow how coverage of this story developed over time